A Post Marketing Surveillance Study to Monitor the Reactogenicity and Safety of Vaxem Hib When Administered According to the Prescribing Information in Korea

Trial Profile

A Post Marketing Surveillance Study to Monitor the Reactogenicity and Safety of Vaxem Hib When Administered According to the Prescribing Information in Korea

Completed
Phase of Trial: Phase IV

Latest Information Update: 10 Sep 2012

At a glance

  • Drugs TAK 816 (Primary)
  • Indications Haemophilus infections
  • Focus Adverse reactions
  • Sponsors Novartis; Novartis Vaccines
  • Most Recent Events

    • 10 Sep 2012 Actual patient number changed from 759 to 764, as reported by ClinicalTrials.gov.
    • 10 Sep 2012 Actual end date (Jul 2012) added as reported by ClinicalTrials.gov.
    • 01 Jul 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top